Serum IGFBP‑3 is a more effective predictor than IGF‑1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection

Aleem,Eiman; Elshayeb,Ayman; Elhabachi,Nihal; Mansour,Amal   Refaat; Gowily,Ahmed; Hela,Asmaa

doi:10.3892/ol.2011.546

Serum IGFBP‑3 is a more effective predictor than IGF‑1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection

Authors:
- Eiman Aleem
- Ayman Elshayeb
- Nihal Elhabachi
- Amal Refaat Mansour
- Ahmed Gowily
- Asmaa Hela
View Affiliations

Affiliations: Molecular Biology Division, Zoology Department, Faculty of Science, Alexandria University, Alexandria, Egypt, Department of Tropical Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt, Department of Physiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt, Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt, Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Published online on: December 30, 2011 https://doi.org/10.3892/ol.2011.546
Pages: 704-712

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) contributes to 14.8% of all cancer mortality in Egypt, which has a high prevalence of hepatitis C virus (HCV). We have previously shown alterations in the insulin-like growth factor-1 (IGF‑1) receptor signalling pathway during experimental hepatocarcinogenesis. The aim of this study was to determine whether serum levels of IGF‑1, IGF‑2 and IGFBP‑3 can be used to discriminate between HCC and the stages of hepatic dysfunction in patients with liver cirrhosis assessed by the Child-Pugh (CP) score, and to correlate these levels with HCC stages. We recruited 241 subjects to the present study; 79 with liver cirrhosis, 62 with HCV-induced HCC and 100 age-matched controls. Results showed that serum levels of IGF‑1, IGF‑2 and IGFBP‑3 were reduced significantly in cirrhosis and HCC patients in comparison to the controls, and that this reduction negatively correlated with the CP scores. However, only IGFBP‑3 levels showed significant negative correlation with α‑fetoprotein levels. The reduction in IGF‑1 and IGFBP‑3 but not IGF‑2 levels was significant in HCC in comparison to patients with cirrhosis. None of the parameters significantly correlated with the HCC stage. IGFBP‑3 levels discriminated between cirrhosis and HCC at a sensitivity of 87%, a specificity of 80% and a cut-off value of <682.6 ng/ml. In conclusion, although our results showed that serum IGF‑1, IGF‑2 and IGFBP‑3 are reduced with the progression of hepatic dysfunction, only IGFBP‑3 may be considered as the most promising serological marker for the prediction of the development of HCC in the chronic HCV patients with liver cirrhosis.

View Figures

View References

1	Hsieh PM, Hung KC and Chen YS: Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol. 15:4726–4728. 2009. View Article : Google Scholar : PubMed/NCBI
2	Anwar WA, Khaled HM, Amra HA, El-Nezami H and Loffredo CA: Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res. 659:176–184. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sievert W, Altraif I, Razavi HA, et al: A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 31(Suppl 2): 61–80. 2011. View Article : Google Scholar : PubMed/NCBI
4	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
5	Furstenberger G and Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol. 3:298–302. 2002. View Article : Google Scholar
6	Nehrbass D, Klimek F and Bannasch P: Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis. Am J Pathol. 152:341–345. 1998.PubMed/NCBI
7	Aleem E, Nehrbass D, Klimek F, Mayer D and Bannasch P: Upregulation of the insulin receptor and type I insulin-like growth factor receptor are early events in hepatocarcinogenesis. Toxicol Pathol. 39:524–543. 2011. View Article : Google Scholar : PubMed/NCBI
8	Rosen CJ and Pollak M: Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab. 10:136–141. 1999. View Article : Google Scholar : PubMed/NCBI
9	Rosenfeld RG, Kofoed E, Little B, et al: Growth hormone insensitivity resulting from post-GH receptor defects. Growth Horm IGF Res. 14(Suppl A): S35–S38. 2004. View Article : Google Scholar : PubMed/NCBI
10	Jones JI and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 16:3–34. 1995.PubMed/NCBI
11	Mazziotti G, Sorvillo F, Morisco F, et al: Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 95:2539–2545. 2002. View Article : Google Scholar
12	Su WW, Lee KT, Yeh YT, et al: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal. 24:195–200. 2010. View Article : Google Scholar : PubMed/NCBI
13	Tovar V, Alsinet C, Villanueva A, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 52:550–559. 2010. View Article : Google Scholar : PubMed/NCBI
14	Sidlova K, Pechova M, Kotaska K and Prusa R: Insulin-like growth factor binding protein-3 in patients with liver cirrhosis. Physiol Res. 51:587–590. 2002.PubMed/NCBI
15	Wu YL, Ye J, Zhang S, Zhong J and Xi RP: Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol. 10:2740–2743. 2004.PubMed/NCBI
16	Bruix J and Llovet JM: Hepatocellular carcinoma: is surveillance cost effective? Gut. 48:149–150. 2001. View Article : Google Scholar : PubMed/NCBI
17	Spangenberg HC, Thimme R and Blum HE: Serum markers of hepatocellular carcinoma. Semin Liver Dis. 26:385–390. 2006. View Article : Google Scholar : PubMed/NCBI
18	Srinivas PR, Kramer BS and Srivastava S: Trends in biomarker research for cancer detection. Lancet Oncol. 2:698–704. 2001. View Article : Google Scholar : PubMed/NCBI
19	Kato N, Yokosuka O, Omata M, Hosoda K and Ohto M: Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest. 86:1764–1767. 1990. View Article : Google Scholar : PubMed/NCBI
20	Aishima S, Basaki Y, Oda Y, et al: High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci. 97:1182–1190. 2006. View Article : Google Scholar
21	McShane LM, Altman DG and Sauerbrei W: Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst. 97:1023–1025. 2005. View Article : Google Scholar : PubMed/NCBI
22	Shaarawy M, Fikry MA, Massoud BA and Lotfy S: Insulin-like growth factor binding protein-3: a novel biomarker for the assessment of the synthetic capacity of hepatocytes in liver cirrhosis. J Clin Endocrinol Metab. 83:3316–3319. 1998. View Article : Google Scholar : PubMed/NCBI
23	Mattera D, Capuano G, Colao A, et al: Increased IGF-I: IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf). 59:699–706. 2003. View Article : Google Scholar : PubMed/NCBI
24	Elsammak MY, Amin GM, Khalil GM, Ragab WS and Abaza MM: Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis. Clin Biochem. 39:623–629. 2006. View Article : Google Scholar
25	Okan A, Comlekci A, Akpinar H, et al: Serum concentrations of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in patients with chronic hepatitis. Scand J Gastroenterol. 35:1212–1215. 2000. View Article : Google Scholar : PubMed/NCBI
26	Hanafusa T, Yumoto Y, Nouso K, et al: Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 176:149–158. 2002. View Article : Google Scholar : PubMed/NCBI
27	Luo SM, Tan WM, Deng WX, Zhuang SM and Luo JW: Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol. 11:4272–4276. 2005.PubMed/NCBI
28	Huynh H, Chow PK, Ooi LL and Soo KC: A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ. 13:115–122. 2002.
29	Park IY, Sohn BH, Yu E, et al: Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology. 132:1476–1494. 2007. View Article : Google Scholar : PubMed/NCBI
30	Shon JK, Shon BH, Park IY, et al: Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res. 139:14–21. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ricort JM, Lombet A, Lassarre C and Binoux M: Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS Lett. 527:293–297. 2002. View Article : Google Scholar
32	Ricort JM and Binoux M: Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway. J Biol Chem. 277:19448–19454. 2002. View Article : Google Scholar : PubMed/NCBI
33	Ricort JM and Binoux M: Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells. Biochem Biophys Res Commun. 314:1044–1049. 2004. View Article : Google Scholar : PubMed/NCBI
34	Weng CJ, Hsieh YH, Tsai CM, et al: Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 17:1808–1815. 2010. View Article : Google Scholar : PubMed/NCBI
35	El-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS and Elsayed AA: Enhanced detection of hepatocellular carcinoma. Cancer Control. 12:248–253. 2005.PubMed/NCBI
36	Rehem RN and El-Shikh WM: Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepato-gastroenterology. 58:949–954. 2011.PubMed/NCBI
37	Scharf JG, Ramadori G and Dombrowski F: Analysis of the IGF axis in preneoplastic hepatic foci and hepatocellular neoplasms developing after low-number pancreatic islet transplantation into the livers of streptozotocin diabetic rats. Lab Invest. 80:1399–1411. 2000. View Article : Google Scholar
38	Price JA, Kovach SJ, Johnson T, et al: Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Hepatology. 36:1089–1097. 2002. View Article : Google Scholar : PubMed/NCBI
39	Qian J, Yao D, Dong Z, et al: Characteristics of hepatic IGF-ii expression and monitored levels of circulating IGF-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol. 134:799–806. 2010. View Article : Google Scholar : PubMed/NCBI
40	El Tayebi HM, Salah W, El Sayed IH, et al: Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. Biomarkers. 16:346–354. 2011.PubMed/NCBI
41	Fan J, Upadhye S and Worster A: Understanding receiver operating characteristic (ROC) curves. CJEM. 8:19–20. 2006.PubMed/NCBI
42	Scott CD, Martin JL and Baxter RC: Production of insulin-like growth factor I and its binding protein by adult rat hepatocytes in primary culture. Endocrinology. 116:1094–1101. 1985. View Article : Google Scholar : PubMed/NCBI
43	Chin E, Zhou J, Dai J, Baxter RC and Bondy CA: Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex. Endocrinology. 134:2498–2504. 1994.PubMed/NCBI
44	Villafuerte BC, Koop BL, Pao CI, Gu L, Birdsong GG and Phillips LS: Coculture of primary rat hepatocytes and nonparenchymal cells permits expression of insulin-like growth factor binding protein-3 in vitro. Endocrinology. 134:2044–2050. 1994.PubMed/NCBI
45	Scharf J, Ramadori G, Braulke T and Hartmann H: Synthesis of insulinlike growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulinlike growth factor, and growth hormone. Hepatology. 23:818–827. 1996. View Article : Google Scholar
46	Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T and Hartmann H: Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis. 19:2121–2128. 1998. View Article : Google Scholar : PubMed/NCBI
47	Stuver SO, Kuper H, Tzonou A, et al: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer. 87:118–121. 2000. View Article : Google Scholar : PubMed/NCBI
48	Major JM, Stolzenberg-Solomon RZ, Pollak MN, Snyder K, Virtamo J and Albanes D: Insulin-like growth factors and liver cancer risk in male smokers. Br J Cancer. 103:1089–1092. 2010. View Article : Google Scholar : PubMed/NCBI
49	Bonefeld K and Moller S: Insulin-like growth factor-I and the liver. Liver Int. 31:911–919. 2011. View Article : Google Scholar : PubMed/NCBI